Takeda Pharmaceutical Co (MEX:TAK N) EPS (Basic): MXN-4.82 (TTM As of Mar. 2026)


MEX:TAK N Takeda Pharmaceutical Co Ltd MEX:TAK N
67 GF Score
Price MXN320.00
GF Value MXN289.17
! 6 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co EPS (Basic)?

Takeda Pharmaceutical Co MEX:TAK N 67 EPS (Basic) is MXN-4.82 as of Mar. 2026. GuruFocus rates MEX:TAK N with a GF Score™ of 67/100 and a GF Value™ of MXN289.17. The stock has 6 warning signs investors should review.

Takeda Pharmaceutical Co's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was MXN-13.30. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-4.82.

Takeda Pharmaceutical Co's EPS (Diluted) for the three months ended in Mar. 2026 was MXN-13.30. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-4.95.

Takeda Pharmaceutical Co's EPS without NRI for the three months ended in Mar. 2026 was MXN-13.30. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -4.95.

During the past 12 months, Takeda Pharmaceutical Co's average EPS without NRIGrowth Rate was -32.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was -32.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -17.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Takeda Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 34.20% per year. The lowest was -32.60% per year. And the median was 2.35% per year.

Takeda Pharmaceutical Co  (MEX:TAK N) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Takeda Pharmaceutical Co EPS (Basic) Related Terms

Takeda Pharmaceutical Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co EPS (Basic) Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.35 13.78 5.10 4.69 -5.50

Takeda Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.49 5.17 -0.49 3.80 -13.30
MEX:TAK N
67GF Score
Takeda Pharmaceutical Co Ltd MEX:TAK N
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Takeda Pharmaceutical Co's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-17317.598-0)/3150.124
=-5.50

Takeda Pharmaceutical Co's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-41873.04-0)/3158.613
=-13.26

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-4.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of MXN-4.82 mean?
Takeda Pharmaceutical Co (MEX:TAK N) has a EPS (Basic) of MXN-4.82 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's EPS (Basic) too high?
Takeda Pharmaceutical Co's current EPS (Basic) is MXN-4.82. Overall, Takeda Pharmaceutical Co has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's EPS (Basic) compare to ZTS and UTHR?
Takeda Pharmaceutical Co's EPS (Basic) of MXN-4.82 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current EPS (Basic) is MXN-4.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Takeda Pharmaceutical Co (MEX:TAK N) has a current EPS (Basic) of MXN-4.82. The stock's GF Value™ is MXN289.17, compared to a current price of MXN320.00 — trading 10.7% above its estimated fair value. The current EPS (Basic) is MXN-4.82. Takeda Pharmaceutical Co's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Takeda Pharmaceutical Co (MEX:TAK N), the current EPS (Basic) is MXN-4.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (MEX:TAK N) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of MXN320.00 is trading 10.7% above its estimated GF Value™ of MXN289.17.

Key valuation signals for MEX:TAK N:

  • EPS (Basic): MXN-4.82
  • GF Value™: MXN289.17 vs. price of MXN320.00 (10.7% above fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the MEX:TAK N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
67GF Score

Get the complete analysis for MEX:TAK N

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN320.00
Price
MXN289.17
GF Value